Medpace Q2 Revenue Climbs 17.2% as Company Raises Full-Year 2026 Guidance

Key Facts

1Medpace Q2 revenues rose 17.2% to $707.3M, driven by a faster backlog burn.

2The company raised its full-year 2026 guidance across revenue, EBITDA, and EPS.

Medpace Q2 revenues rose 17.2% to $707.3 million, driven by a faster backlog burn. Seeking Alpha reported that the company raised its full-year 2026 guidance across revenue, EBITDA, and earnings per share.

MEDP closed at $620.05 on October 12, 2026, with a session high of $623.11 and a low of $608.71. The improved financial outlook addresses market concerns over backlog quality, as stronger margins and customer prepayments continue to support the company's financial performance and buyback programs.